Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Immunotherapy of cancer 2

2016 - Discrepancy of tumor neoantigen burden between primary lesions and matched metastases in lung cancer


22 Oct 2018


Poster Discussion session - Immunotherapy of cancer 2


Tumour Immunology

Tumour Site


Tao Jiang


Annals of Oncology (2018) 29 (suppl_8): viii400-viii441. 10.1093/annonc/mdy288


T. Jiang, C. Zhou

Author affiliations

  • Medical Oncology, Shanghai Pulmonary Hospital, Tongji University, 200433 - Shanghai/CN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2016


Personalized vaccine based on tumor neoantigens showed the striking antitumor effect on several solid tumors, suggesting its significant role in curing cancer. However, whether tumor neoantigens identified from primary lesions were similar to their matched metastases remain unknown. Here, we aimed to compared the tumor neoantigen burden (TNB) between primary lesions and matched metastases in lung cancer.


Primary lung cancers, matched metastases and peripheral blood were collected before any systemic therapy as part of the standard clinical care. DNA libraries were subjected to whole-exome capture and sequenced on an Illumina HiSeq X-TEN platform. The criteria for tumor neoantigen were tumor specific mutations, fold change > 10, high predicted affinity (IC50 < 500 nM) and predicted peptide of 9-10 amino acids in length.


14 cases with matched lung primary lesions and metastases were enrolled, including 10 cases with liver metastases (LM) and 4 with brain metastases (BM). A wide range of TNB were identified in both primary lesions (median 157, range 21-1156) and metastases (median 135, range 35-1902). We observed a large discrepancy of TNB between primary lesions and matched metastases, with a median unique percentage of 82.20% (74.03%-95.24%) in primary lesions and 84.50% (77.45%-97.14%) in metastases. In patients with BM, primary lesions had a percentage of 90.98% (79.57%-95.24%) unique tumor neoantigens, while metastases had 86.03% (77.45%-97.14%). For those with LM, the median unique percentage of tumor neoantigens was 80.58% (74.03%-88.66%) in primary lesions and 83.35% (78.49%-91.14%) in metastases. Smoking history and histological types had no impact on the discrepancy of TNB (P > 0.05, P > 0.05; respectively). TNB of primary lesions was similar to matched metastases (P = 0.733). However, primary lesions of BM had a significantly higher percentage of unique tumor neoantigen than that of LM (P = 0.025).


There is a large percentage of different tumor neoantigens between primary lesions and matched metastases in lung cancer. Whether this discrepancy could affect the efficacy of following personalized vaccine on primary lesions or matched metastases need further exploration.

Clinical trial identification

Legal entity responsible for the study

Caicun Zhou.


Has not received any funding.

Editorial Acknowledgement



All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.